Home > Clinical Trials

Saved trials

RECRUITING
NCT07478991
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
376 Enrollment(s)
52 Study location(s)
INTERVENTIONAL (PHASE3)
Acute Myeloid Leukemia, Adult
RECRUITING
NCT06324396
IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease
15 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Fontan Circulation
RECRUITING
NCT05564390
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
2,000 Enrollment(s)
360 Study location(s)
INTERVENTIONAL (PHASE2)
Acute Myeloid Leukemia


Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm


Acute Myeloid Leukemia Post Cytotoxic Therapy


Acute Myeloid Leukemia, Myelodysplasia-Related


Myelodysplastic Syndrome
NOT_YET_RECRUITING
NCT07905313
Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)
60 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer (Advanced/Metastatic)
RECRUITING
NCT06819007
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
582 Enrollment(s)
232 Study location(s)
INTERVENTIONAL (PHASE3)
Ovarian Cancer
RECRUITING
NCT06324357
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
910 Enrollment(s)
104 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Metastatic Breast Cancer


Metastatic Gastric Adenocarcinoma


Gastroesophageal Junction Adenocarcinoma


Esophageal Adenocarcinoma


Colorectal Cancer
COMPLETED
NCT05681702
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
84 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Artery Disease
RECRUITING
NCT04616560
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
55 Enrollment(s)
32 Study location(s)
INTERVENTIONAL (PHASE2)
Desmoplastic Small Round Cell Tumor


Osteosarcoma


Recurrent Desmoplastic Small Round Cell Tumor


Recurrent Kidney Wilms Tumor


Recurrent Osteosarcoma


Refractory Desmoplastic Small Round Cell Tumor


Refractory Wilms Tumor


Wilms Tumor